

www.eano.eu



#EANO2023

Photo © Rotterdam Partners



18TH MEETING & EDUCATIONAL DAY
OF THE EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

EANO 2023

ROTTERDAM, NETHERLANDS

PROGRAMME

SEPT 21 - 24, 2023

DE DOELEN –

ICC ROTTERDAM




NCT05580562

The ACTION Study



A randomized Phase 3 study of ONC201 in patients with newly diagnosed H3 K27M-mutant diffuse glioma



- The H3 K27M mutation occurs in both pediatric and adult patients with glioma^{1,2}
- ONC201, a first-in-class imipridone, is a selective small molecule antagonist of DRD2 and agonist of ClpP
- Previous open-label experience with ONC201 in patients with H3 K27M-mutant glioma, including Phase 2 data demonstrating a RANO HGG/LGG response rate of 30%, has been reported³⁻⁵

The ACTION study (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group international Phase 3 trial of patients with newly diagnosed, H3 K27M-confirmed diffuse glioma after completion of radiotherapy.

Eligibility Criteria

- H3 K27M-mutant diffuse glioma
 - H3 K27M mutation by IHC or NGS
- ≥ 10 kg body weight
- 2–6 weeks since radiotherapy
- KPS/LPS ≥ 70
- Stable or decreasing corticosteroids and anti-seizure medication for seven days
- Not eligible: Spinal tumors, DIPG, leptomeningeal spread, CSF dissemination

1:1 Randomization (2–6 weeks post RT)

Twice-weekly
ONC201
(625 mg)

Once-weekly
ONC201
(625 mg)

Placebo

Primary Outcomes

Efficacy: OS, PFS

Secondary Endpoints

Safety: AE incidence, change from baseline

Efficacy: PFS in patients with measurable, contrast-enhancing disease

Clinical benefit: Corticosteroid response, performance status response

QoL: EORTC-QLQ-C30, QLQ-BN20, MDASI-BT, PedsQL, NANO

Planned Enrollment: 450 patients

Please join us for a Sponsored Satellite Symposium

H3 K27M-mutant Diffuse Glioma:
Diagnosis to Treatment and
Future Directions

Saturday, September 23rd
Grote Zaal | 13:00–14:00

For more information,
please visit us at booth #1,
scan QR code, or contact us
at clinicaltrials@chimerix.com



References

1. Lulla RR, et al. Sci Adv. 2016;2(3):e1501354; 2. Khuong-Guang DA, et al. Acta Neuropathol. 2012;124(3):439-47; 3. Arrillaga-Romany I, et al. Oncotarget. 2017;8(45):79298-79304; 4. Arrillaga-Romany, I, et al. Neuro Oncol. 2022;22(1):94-102; 5. Arrillaga-Romany I, et al. Neuro Oncol. 2021;23(Supplement_6):vi230-vi230.

Presidential Address	4
Board, Scientific Committee, Organisation	5
Programme Overview	6 - 9
Side Meetings	10
Poster Information	11
Save the Date EANO 2024	12
Corporate Symposia	13
Sponsors & Exhibitors	14
General Information	15 - 18
Networking Events	20 - 21
Floor Plans	22 - 23

EANO 2023 CONGRESS APP

Everything important at a glance!

Download for free and put the congress in your pocket now!

Scan QR-Code:



Or search for „Floq by Conference Compass“ in the App Store:






Dear EANO members, colleagues and friends,

Welcome to the 18th Meeting of the European Association of Neuro-Oncology (EANO 2023) in the splendid environment of Rotterdam.

The Congress will kick off with an Educational Day on Thursday, September 21st followed by the main scientific programme from Friday, September 22nd to Sunday September 24th.

Speakers from across the globe will present the latest clinical trial outcomes and highlight critical advances in basic and translational science. Key clinical themes include experimental and combination therapies, the latest on radiation oncology technologies, neurosurgical precision tools, advanced imaging modalities and the latest developments in molecular diagnostics.

Join us in bridging science, knowledge, and clinical practice in the management of CNS malignancies and make the most of opportunities to exchange and collaborate between all relevant disciplines - Neuro-Oncology, Neurosurgery, Neuropathology, Neuroradiology, and Radiation Oncology as well as Nursing and other Allied Health Professionals.

We wish you all an enjoyable and fruitful congress!

Martin van den Bent
President EANO Meeting 2023

& **Susan Short**
EANO President



EANO Executive Board

President: Susan Short,
United Kingdom

Past President: Matthias Preusser,
Austria

Treasurer: Roberta Rudà, Italy

Members:

Anna Berghoff, Austria
Anthony Chalmers, United Kingdom
Christian Mawrin, Germany
Emilie Le Rhun, Switzerland
Evangelia Razis, Greece
Giuseppe Minniti, Italy
Lena Rosenlund, Sweden

EANO Scientific Committee

Chair: Manuel Valiente, Spain

Past-Chair: Michael Platten, Germany

Members:

Anna Berghoff, Austria
Anna Golebiewska, Luxemburg
Antonella Castellano, Italy
Asgeir Jakola, Sweden
Benedikt Hasselbalch, Denmark
Dieter Henrik Heiland, Germany
Estela Pineda Losada, Spain
Felix Sahm, Germany
Franziska Ippen, Germany (Youngster Representative)
Giuseppe Minniti, Italy
Martin van den Bent, Netherlands
Pim French, The Netherlands
Susan Short, United Kingdom
Tareq Juratli, Germany

EANO Congress Organiser

European Association of
Neuro-Oncology c/o WMA GmbH
Alser Strasse 4
1090 Vienna, Austria

Congress President:

Martin van den Bent, Netherlands

Scientific Management,
Exhibition and Sponsorship,
General Organisation and Logistics
WMA GmbH
Lydia Schnedl
Julian Piskula

T: +43 1 4051383-14

E: eano-meetings@eano.eu

W: www.eano.eu/eano2023

EANO Office

Alissa McGregor
c/o WMA GmbH
Alser Strasse 4
1090 Vienna, Austria
T: +43 1 4051383-41
E: office@eano.eu
W: www.eano.eu



www.eano.eu

EANO

EUROPEAN ASSOCIATION
OF NEURO-ONCOLOGY

THURSDAY SEPTEMBER 21, EDUCATIONAL DAY

	Educational Day Basic Science track	Educational Day Clinical track	Educational Day Nurses/AHPs track
Room/Floor	WILLEM BURGER ZAAL Third Floor	VAN WEELDE ZAAL (10) Fourth Floor	RUYS ZAAL (8) Fourth Floor
08.55 - 10.00	EDB01 Where Do Drugs Go?	EDC01 Rare Entities	EDN01 Quality of life and survivorship
10.00 - 10.10	TIME TO CHANGE ROOMS		
10.10 - 11.30	EDB02 What is the Tumour Microenvironment?	EDC02 (incl. Nurses/AHPs track) Latest updates in gliomas	
11.30 - 12.00	COFFEE BREAK		
12.00 - 13.15	EDB03 What is tumour heterogeneity?	EDC03 Targeted therapy for brain tumours	EDN02 (12.00 - 13.20) Family-focused practice and caregiver support
13.15 - 14.00	LUNCH BREAK		
14.00 - 15.20	EDB04 How do tumours become resistant to treatment?	EDC04 Brain Metastases - Pros and Cons	EDN03 (14.00 - 15.15) Clinical outcome assessments
15.15 - 15.35	COFFEE BREAK		
15.35 - 16.35	EDB05 Biostatistics for the neuro-oncologist	EDC05 Advanced imaging for brain tumours	EDN04 Interdisciplinarity in neuro-oncology
16.35 - 17.00	BREAK		
	EANO Meeting		
17.00 - 18.00	JS01 EANO-EANS Youngsters Treatment of rare CNS tumors	OS01 Emerging themes and novel treatments	PD01 Neuro-Oncology Unplugged

FRIDAY SEPTEMBER 22, EANO MEETING

Room/Floor	GROTE ZAAL First Floor	WILLEM BURGER ZAAL Third Floor	VAN WEELDE ZAAL (10) Fourth Floor	RUYS ZAAL (8) Fourth Floor
08.00 - 09.00	ME01 Modern manage- ment in brain metastases	ME02 Application of focused ultrasound in brain tumours	ME03 New technology for re-irradiation	
09.00 - 09.15	TIME TO CHANGE ROOMS			
09.15 - 10.45	OS02 Addressing recruit- ment and disparity in clinical trials	JS02 EANO-EORTC Research and pub- lication landscape	OS03 Diagnostics meets Artificial Intelligence	
10.45 - 11.15	COFFEE BREAK			
11.15 - 11.30	Opening and Presi- dential Address			
11.30 - 13.00	PL01 Exploiting the immune system to challenge brain tumors			
13.00 - 14.30	LUNCH BREAK			
13.15 - 14.15	CS01 Corporate Sympo- sium		CS02 Corporate Sympo- sium	WS01 EANO Youngsters Mentoring: The two sides of publishing: the editor's and re- viewer's perspective
14.30 - 16.00	KS01 Antibody-drug conjugates and other advanced therapeutics in Neuro-Oncology	OS04 Adjuvant treat- ment in Low Grade Gliomas	OS05 eHealth in Neuro- Oncology	
16.00 - 16.15	TIME TO CHANGE ROOMS			
16.15 - 17.45	KS02 Therapies for IDH- mutant gliomas	PC01 Complexity of tech-demanding neuropathology	JS03 EANO-EAN Impact on brain function by tumors or their treatments	
17.45 - 18.00	TIME TO CHANGE ROOMS			
18.00 - 19.30	18.00 - 18.30 Poster Pitches 18.00 - 19.30 Poster Viewing with authors I Grote Zaal Foyer			

SATURDAY SEPTEMBER 23, EANO MEETING

Room/Floor	GROTE ZAAL First Floor	WILLEM BURGER ZAAL Third Floor	VAN WEELDE ZAAL (10) Fourth Floor
08.00 - 09.00	ME04 EANO guidelines 2023	ME05 New technical developments in glioblastoma	ME06 Management of vestibular schwannomas
09.00 - 09.15	TIME TO CHANGE ROOMS		
09.15 - 10.45	JS04 EANO-SNO Management of CNS tumors in the molecular era	JS05 EANO-EANS Surgical treatment of brain tumors	OS06 Radiomics in Neuro-Oncology
10.45 - 11.15	COFFEE BREAK		
11.15 - 12.45	OS07 Disease progression with high dimensional techniques	OS08 Quality of life and symptoms	OS09 Highlights from abstracts
12.45 - 14.15	LUNCH BREAK		
13.00 - 14.00	CS03 Corporate Symposium	CS04 Corporate Symposium	WS02 EANO Youngsters: How to survive: Neuropathology
14.15 - 15.45	OS10 Implications of neuron- and glial-like phenotypes in brain tumors	OS11 EANO Youngsters: Discussions on clinical controversies	OS12 Brain tumors in AYA population
15.45 - 16.00	TIME TO CHANGE ROOMS		
16.00 - 17.00	JS06 EANO-ESTRO Optimizing radiosurgery and other therapeutic options for brain metastases	PL02 Award Winning Abstracts	JS07 EANO-EURACAN EURACAN: Progress in the EU Rare cancers network
17.00 - 17.15	TIME TO CHANGE ROOMS		
17.15 - 19.30	17.15 - 17.45 Poster Pitches 18.00 - 19.30 Poster Viewing with authors II Grote Zaal Foyer		

SUNDAY SEPTEMBER 24, EANO MEETING

Room/Floor	WILLEM BURGER ZAAL Third Floor	VAN WEELDE ZAAL (10) Fourth Floor
08.00 - 09.00	EANO General Assembly	
09.00 - 10.30	KS03 Meningioma	JS08 EANO-EACR Strategies to develop patient avatars or other patient surrogates for precision oncology
10.30 - 11.00	COFFEE BREAK	
11.00 - 12.30	OS13 The role of population-based registries and retrospective studies in neuro-oncology	JS09 EANO-EANM PET and MRI in patients with brain tumors
12.30 - 12.45	Closing Remarks	

PROGRAMME CHANGES

All contents are as per date of printing August 25, 2023.

The up-to-date scientific programme is available in the online programme on the congress website and in the congress app.

The organiser reserves the right to modify the programme in case of external or unforeseen circumstances and cannot assume any liability. No refunds can be granted in case of cancellations of speakers, lack of space in the conference room or any other incidents during the congress which are beyond the control of the organiser.

LEGEND ABBREVIATIONS

- JS Joint Session
- KS Keynote Session
- ME Meet the Experts
- OS Oral Session
- PC Pro & Con Session
- PD Panel Discussion
- PL Plenary Session
- WS Workshop



Full Programme

SIDE MEETINGS

Information as per date of printing.

THURSDAY, SEPTEMBER 21

<i>Time</i>	<i>Meeting</i>	<i>Room/Floor</i>	<i>Type</i>
15.30 - 17.00	Biomarker Consortium	Hudig Zaal (2), Third Floor	Closed

FRIDAY, SEPTEMBER 22

<i>Time</i>	<i>Meeting</i>	<i>Room/Floor</i>	<i>Type</i>
07.30 - 08.30	Trident Investigator Meeting	Hudig Zaal (2), Third Floor	Closed
08.00 - 09.00	EURACAN Meeting	Ruys Zaal (8), Third Floor	Closed
10.45 - 11.15	EANO Scientific Committee and Working Party	Hudig Zaal (2), Third Floor	Closed
11.45 - 13.00	EANO Nurse & Allied Health Professional Committee (NAC)	Hudig Zaal (2), Third Floor	Closed
13.15 - 14.15	EANO Molec Tumour Board Meeting	Willem Burger Zaal, Third Floor	Open
13.15 - 14.15	Curevac Investigator Meeting	Hudig Zaal (2), Third Floor	Closed
18.00 - 19.00	EANO 2023 Meet the Industry Meeting	Van der Mandele Zaal, First Floor	Closed
18.00 - 19.30	Meet the Editors/Authors: Neuro-Oncology Compendium for the Boards and Clinical Practice Oxford Academic (oup.com)	Grote Zaal Foyer (EANO Community Area), First Floor	Open
19.00 - 20.00	EANO Early Career Initiative	Ruys Zaal (8), Third Floor	Closed

SATURDAY, SEPTEMBER 23

<i>Time</i>	<i>Meeting</i>	<i>Room/Floor</i>	<i>Type</i>
13.00 - 14.00	EANO Educational Committee	Ruys Zaal (8), Third Floor	Closed
13.30 - 14.30	EORTC Nuclear Medicine Committee Meeting	Hudig Zaal (2), Third Floor	Closed
17.15 - 18.15	National Societies Get-together	Van der Mandele Zaal, First Floor	Closed

POSTER PRESENTATIONS

The posters have been divided into two separate poster viewing with authors sessions. Both poster numbers for both days will be shown on the poster board. The first poster number indicates the poster presented during the first poster session on Friday, the second poster number indicates the poster presented during the second poster session on Saturday.

To enable discussion and interaction with participants, it is mandatory for poster presenters or one of their group members to be present at the poster board during the according poster session.

SCHEDULE FOR DISPLAY, MOUNTING AND REMOVAL

Friday, September 22, 2023

Posters with poster numbers ending with "A" will be presented (e.g. P01.01.A).

Poster Viewing with authors I, 18.00 - 19.30 hrs

Poster mounting: as of 07.30 hrs

Poster removal: 19.30 - 20.00 hrs

Saturday, September 23, 2023

Posters with poster numbers ending with "B" will be presented (e.g. P01.02.B).

Poster Viewing with authors II, 17.15 - 18.45 hrs

Poster mounting: as of 07.30 hrs

Poster removal: 18.45 - 19.15 hrs

POSTER TOPICS

- | | |
|--|--|
| 01. Cognition in brain tumors | 12. Tumor microenvironment |
| 02. Tumor heterogeneity, plasticity and impact on therapeutic response | 13. Artificial intelligence/Machine learning/Computation |
| 03. Radiation technologies/Radiobiology/Radiotoxicity/Radiosensitizers | 14. Liquid biomarkers |
| 04. Pediatric brain tumors | 15. Development and validation of innovative imaging strategies (PET, metabolic MRI) |
| 05. Multilayer diagnostics | 16. Leptomeningeal disease |
| 06. Immunotherapy | 17. Recurrent glioblastoma |
| 07. Advanced techniques in Neuro-Oncology | 18. Meningioma |
| 08. QoL/Palliative care, end of life and care giving | 19. Cancer-Neuroscience |
| 09. Symptoms and symptom management | 20. Rare CNS tumors |
| 10. Preclinical neuro-oncology | 21. Epidemiology/ Biobanks/ National registries |
| 11. Clinical neuro-oncology | 22. Patient and public involvement |

ABSTRACTS

Abstracts presented at the EANO 2023 are available on the congress app, the congress website and in the September digital issue of the journal "NeuroOncology".

EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

EANO 2024 GLASGOW

Scottish Event Campus (SEC) • Glasgow, United Kingdom



*See you
there!*



www.eano.eu

19TH MEETING & EDUCATIONAL DAY

OVERVIEW OF CORPORATE SYMPOSIA


FRIDAY, SEPTEMBER 22

<i>Time</i>	<i>Title</i>	<i>Company</i>	<i>Room/Floor</i>
13.15 - 14.15	CS01 New Developments in Glioma Care: A Focus on Mutant IDH Inhibition*	Servier	Grote Zaal, First Floor
13.15 - 14.15	CS02 Improving Patient Care: New Perspectives on HDMTX Treatment in Neuro-Oncology*	SERB Pharmaceuticals	Van Weelde Zaal, Fourth Floor

SATURDAY, SEPTEMBER 23

<i>Time</i>	<i>Title</i>	<i>Company</i>	<i>Room/Floor</i>
13.00 - 14.00	CS03 H3 K27M-mutant Diffuse Glioma: Diagnosis to Treatment and Future Directions	Chimerix	Grote Zaal, First Floor
13.00 - 14.00	CS04 Tumor Treating Fields: In Application*	Novocure	Willem Burger Zaal, Third Floor

*Lunch boxes will be provided to the session attendees.



SPONSORS

Platinum Sponsor



Silver Sponsor



General Sponsors

Carthera

Medac

Stichting STOPhersentumoren

EXHIBITORS

Blue Earth Diagnostics Ltd

Brain Tumour Charity

Chimerix

Medtronic

Focused Ultrasound Foundation

Novocure

SERB

Servier

Wisepress

European Association
of Neuro-Oncology (EANO)

GENERAL INFORMATION

Opening hours

Registration

WILLEM BURGER HAL, Ground Floor

Wednesday, September 20, 2023	16.00 - 19.00 hrs
Thursday, September 21, 2023	08.00 - 18.30 hrs
Friday, September 22, 2023	07.30 - 19.00 hrs
Saturday, September 23, 2023	07.30 - 18.00 hrs
Sunday, September 24, 2023	07.30 - 11.30 hrs

Speaker Service Centre

SCHADEE ZAAL, 3rd Floor

Wednesday, September 20, 2023	16.00 - 19.00 hrs
Thursday, September 21, 2023	08.00 - 18.00 hrs
Friday, September 22, 2023	07.30 - 18.00 hrs
Saturday, September 23, 2023	07.30 - 17.00 hrs
Sunday, September 24, 2023	07.30 - 10.00 hrs

Exhibition

GROTE ZAAL FOYER & FEESTZAAL, 1st Floor

Thursday, September 21, 2023	09.00 - 17.30 hrs
Friday, September 22, 2023	09.00 - 19.30 hrs
Saturday, September 23, 2023	09.00 - 18.45 hrs
Sunday, September 24, 2023	CLOSED

Poster Area

GROTE ZAAL FOYER, 1st Floor

Thursday, September 21, 2023	CLOSED
Friday, September 22, 2023	08.00 - 19.30 hrs
Saturday, September 23, 2023	08.00 - 18.45 hrs
Sunday, September 24, 2023	CLOSED

Cloakroom

WILLEM BURGER HAL, Ground Floor

Wednesday, September 20, 2023	16.00 - 19.00 hrs
Thursday, September 21, 2023	08.00 - 18.30 hrs
Friday, September 22, 2023	07.30 - 20.00 hrs
Saturday, September 23, 2023	07.30 - 19.00 hrs
Sunday, September 24, 2023	07.30 - 13.15 hrs

Reimagining Nuclear Medicine

Transforming patients' lives by leading innovation

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through **technology leadership in R&D** and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About **108,000 people** of more than **140 nationalities** work together to bring Novartis products to nearly **800 million people** around the world.



Rich Oncology Pipeline

Targeting multiple tumor types



Reimagining

Nuclear medicine by developing drugs for targeted radioligand therapy and precision radioligand imaging

 NOVARTIS

Location and Accessibility



Congress Venue

De Doelen – ICC Rotterdam
Willem Burger Entrance
Kruisplein 40
3012 CL Rotterdam
The Netherlands

www.dedoeleniccrotterdam.nl

WIFI

Network: DeDoelen
Password: E.Flipse@62

Public transport

De Doelen lies in the city centre and can best be reached by public transport. Buses, trains, metros and trams all stop at **Rotterdam Central Station** which is just a 5-minute walk from de Doelen.

Rotterdam

For information about Rotterdam, visit the congress website: <https://www.eano.eu/eano2023/myconference/rotterdam/>

Congress Policy

Badges

Permission to the congress (scientific sessions, exhibition and poster area) is only permitted to registered participants. Therefore, wearing your badge throughout the entire congress is mandatory!

Language

The official language of the congress is English (no simultaneous translation available).

CME Credits

As in previous years, the European Association of Neuro-Oncology has applied for accreditation from the European Accreditation Council of Continuing Medical Education (UEMS EACCME®) in order to provide participants with the possibility of obtaining CME credits at the congress. The accreditation is still pending at the time of printing this programme. Please see the EANO 2023 website for the latest updates: <https://www.eano.eu/eano2023/myconference/cme-credits/>



Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Certificate of attendance

Confirmations of attendance will be issued via email to all participants after the congress.

Catering

During the morning coffee breaks, refreshments (coffee, tea and snacks) will be served free of charge to participants wearing name badges in the exhibition area.

During the lunch breaks, a light lunch as well as coffee and tea will be offered free of charge to participants wearing name badges in the exhibition area. Lunch boxes will be provided at the Corporate Symposia CS01, CS02 and CS04 to the session attendees

Additionally, water will be provided for free on all floors and coffee will be provided during the day in the exhibition area.

Smoking Policy

The EANO 2023 is officially a “no-smoking-congress”. Note that smoking is banned in the Netherlands in public places (e.g. restaurants, shops, public transport, entertainment venues).

Sustainability

The EANO is committed to environmental sustainability, a responsible use of resources and sustainable congress materials. The organizer therefore asks you to keep these aspects in mind, e.g. by using public transport to get to the venue and networking events, bringing your own water bottle to the congress and by using the existing possibilities for waste separation.

EANO 2024 SEMINARS

Foundations in Neuro-Oncology

© www.depositphotos.com

Warsaw - Palace of Culture and Science

Foto: Photocreo (48610805)

SAVE THE DATE

MARCH 15 - 16, 2024
WARSAW / POLAND

The **EANO Seminars** aims to provide an update on the recent advances in the pathogenesis and management of CNS tumors with particular attention devoted to the application in the clinical practice. The educational event will include lectures and case-based workshops, and is aimed to attract scientists, physicians and healthcare professionals involved in diagnosis and treatment of brain tumors.



EANO
YOUNGSTERS
www.eano.eu

**EUROPEAN ASSOCIATION
OF NEURO-ONCOLOGY**

www.eano.eu

NICE TO MEET YOU!

Please note that the number of participants for all networking events is limited and advance registration is mandatory for each event. Admission will only be granted with a valid ticket. Check ticket availability at the registration desk.

No sponsoring is used to fund any part of the EANO 2023 Networking Events.

Networking Event

Location: Wereldmuseum Rotterdam
Date: Thursday, September 21, 2023
Time: 18.30 - 21.00 hrs



Address: Willemskade 25, 3016 DM Rotterdam
Public transport: Tramway 7 Station „Willemskade“
Individual arrival.

Spend a nice evening with your colleagues while enjoying finger food and drinks with a view of one of the most impressive skylines of the Netherlands.

Dresscode: casual

Youngsters Networking Night

Location: La Cubanita Rotterdam
Date: Friday, September 22, 2023
Time: 20.00 - 24.00 hrs



Address: Oostmolenwerf 14-24, 3011 TL Rotterdam
Public transport: Metro A, B or C or Tramway 21 or 24 Station „Oostplein“
Individual arrival.

Join the EANO Youngsters Networking Night and socialise with other young scientists. You can expect a relaxed atmosphere among other young colleagues from Europe and the world with tapas, table soccer and drinks (3 drinks are included in the price).

Dresscode: casual

EANO Evening

Location: Dinner Cruise on Paddle Steamer De Majesteit
Date: Saturday, September 23, 2023
Time: 19.30 - 23.30 hrs



Address: Maasboulevard, 3063 NS Rotterdam (mooring)
Public transport: Tramway 21 or 24 Station „Willem Ruyslaan“ or Metro A, B or C Station „Oostplein“
Individual arrival.

Spend a wonderful evening with your colleagues and friends on one of the biggest paddle steamers of Europe. You will be able to enjoy food and drinks together with live music in a nostalgic atmosphere.

Dresscode: casual

Attention: Arrive on time! It is not possible to enter the boat during the cruise.


FUTURE EANO MEETINGS:

EANO 2024 - October 17-20, 2024 | Scottish Event Campus (SEC), Glasgow (UNITED KINGDOM)


EANO 2025 - October 15-19, 2025 | Prague Congress Centre, Prague (CZECHIA)




Ground floor




First floor




Second floor



Third floor



Fourth floor





**Delayed MTX elimination
can be an oncologic emergency¹⁻³**



BE READY TO ACT

VORAXAZE®
(glucarpidase)

1 000 units/vial for intravenous injection

Communication restricted to healthcare professionals
Summary of Product Characteristics (SmPC) available
at SERB's booth

Voraxaze® is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.⁴

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

1. Widemann BC, *et al.* J Clin Oncol. 2010;28:3979-86. 2. Ramsey LB, *et al.* Oncologist. 2018;23:52-61.
3. Howard SC, *et al.* Oncologist. 2016;21:1471-82. 4. Summary of Products Characteristics Voraxaze®, current version.

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Reimagining Nuclear Medicine

Transforming patients' lives by leading innovation

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through **technology leadership in R&D** and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About **108,000 people** of more than **140 nationalities** work together to bring Novartis products to nearly **800 million people** around the world.



Rich Oncology Pipeline

Targeting multiple
tumor types



Reimagining

Nuclear medicine by
developing drugs for targeted
radioligand therapy and
precision radioligand imaging

 **NOVARTIS**

Optune® for newly diagnosed grade 4 glioma



Optune has been proven to provide long-term quality survival to patients with newly diagnosed grade 4 glioma^{1,2,*†}

Learn more about how
Optune has extended survival
in a real-world setting³ at

BOOTH #7



Gill is an Optune user. Patient image reflects the health status of the patient at the time the photo was taken.

Mild-to-moderate skin irritation, the most common device-related adverse event with Optune, was manageable, reversible, and did not result in treatment discontinuation⁴

*EF-14 was a prospective, randomized, open-label, phase 3 clinical trial in 695 adult patients with newly diagnosed grade 4 glioma. The trial assessed safety and demonstrated increased median PFS and OS of Optune + TMZ vs TMZ alone.²

†Optune is intended for the treatment of adult patients with newly diagnosed WHO grade 4 glioma. WHO grade 4 gliomas in adult patients include glioblastomas *IDH*-wildtype and astrocytomas grade 4, *IDH*-mutated.

IDH, isocitrate dehydrogenase; OS, overall survival; PFS, progression-free survival; TMZ, temozolomide.

References: **1.** Optune. Instructions for Use for Glioblastoma Multiforme. Novocure; 2019. **2.** Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma. A secondary analysis of a randomized clinical trial. *JAMA Oncol.* 2018;4(4):495-504. doi:10.1001/jamaoncol.2017.5082. **3.** Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM. Association of tumor treating fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. *J Neurooncol.* Published online July 26, 2023. doi:10.1007/s11060-023-04348-w **4.** Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA.* 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718